Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Evercore Wealth Management LLC

Evercore Wealth Management LLC cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 298,083 shares of the medical research company's stock after selling 911 shares during the period. Thermo Fisher Scientific comprises about 2.3% of Evercore Wealth Management LLC's holdings, making the stock its 14th largest position. Evercore Wealth Management LLC owned about 0.08% of Thermo Fisher Scientific worth $155,072,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. increased its position in Thermo Fisher Scientific by 9.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 390,315 shares of the medical research company's stock worth $203,054,000 after purchasing an additional 32,591 shares in the last quarter. Coppell Advisory Solutions LLC grew its holdings in shares of Thermo Fisher Scientific by 21.6% during the fourth quarter. Coppell Advisory Solutions LLC now owns 276 shares of the medical research company's stock worth $144,000 after buying an additional 49 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 86.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after buying an additional 1,433,444 shares during the period. Pinebridge Investments L.P. boosted its position in Thermo Fisher Scientific by 26.6% during the fourth quarter. Pinebridge Investments L.P. now owns 125,815 shares of the medical research company's stock worth $65,453,000 after acquiring an additional 26,466 shares during the last quarter. Finally, Alta Advisers Ltd raised its holdings in Thermo Fisher Scientific by 26.6% in the 4th quarter. Alta Advisers Ltd now owns 1,266 shares of the medical research company's stock valued at $659,000 after acquiring an additional 266 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock valued at $13,106,062 in the last three months. 0.34% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on TMO shares. Royal Bank of Canada set a $693.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research note on Friday, January 31st. StockNews.com upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Finally, Raymond James restated an "outperform" rating and set a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average price target of $642.67.

Thermo Fisher Scientific Trading Up 2.9 %

Shares of NYSE TMO opened at $434.17 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $409.85 and a 12-month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock's 50 day simple moving average is $493.38 and its 200 day simple moving average is $530.71. The company has a market cap of $163.90 billion, a price-to-earnings ratio of 26.27, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is 10.41%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.